Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company...

Read More